Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ.



from The Medical News http://www.news-medical.net/news/20150413/Eisai-Arena-complete-two-Phase-1-registrational-trials-for-once-daily-formulation-of-lorcaserin.aspx